In February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.

I believe we are about to do it again with this new AI project called Stargate

Peter Fromen Biography and Net Worth

Insider of Pacific Biosciences of California

Peter Fromen brings over twenty years of experience from the life sciences and genomics industries, building and leading teams in numerous areas of responsibility. Peter joined Pacific Biosciences after 14 years at Illumina, where most recently he served as Global Vice President of Population Genomics and Precision Health and was responsible for product management, market development, and market strategy across Genetic Disease Research and Testing, Population Genomics, Health Systems and Consumer Genomics. Peter joined Illumina in 2007 to build and lead the firm’s first investor relations function before he transitioned to the commercial organization, leading product marketing activities across multiple business units, and had a leading role in launching several of the company’s high-throughput sequencers. In 2015, with population genomics starting to emerge, Peter relocated to London to oversee Illumina’s partnership with Genomics England and the National Health Service (NHS) to execute the 100,000 Genomes Project and subsequently embed clinical whole genome sequencing as standard of care in the NHS Genomic Medicine Service for rare disease and cancer patients. In this role, Peter and his team were responsible for expanding the company’s global Population Genomics business to enable precision medicine at a population level from market development to enterprise sales.

Prior to joining Illumina, Peter held leadership positions at Applied Biosystems and Agilent Technologies in corporate finance and investor relations roles. He first entered the life sciences industry on the investment side while at Howard Capital Management in New York as an equity research analyst and portfolio manager covering life sciences and technology companies. Peter holds a bachelor’s degree in History with a concentration in Environmental Science from Kenyon College, and an MBA from the W. P. Carey School of Business at Arizona State University.

How do I contact Peter Fromen?: The corporate mailing address for Mr. Fromen and other Pacific Biosciences of California executives is 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025. Pacific Biosciences of California can also be reached via phone at (650) 521-8000 and via email at [email protected]. Learn More on Peter Fromen's contact information.
Has Peter Fromen been buying or selling shares of Pacific Biosciences of California?: Peter Fromen has not been actively trading shares of Pacific Biosciences of California in the last ninety days. Most recently, Peter Fromen sold 19,720 shares of the business's stock in a transaction on Tuesday, January 11th. The shares were sold at an average price of $14.30, for a transaction totalling $281,996.00. Learn More on Peter Fromen's trading history.
Who are Pacific Biosciences of California's active insiders?: Pacific Biosciences of California's insider roster includes (Pres), William Ericson (Director), Peter Fromen (Insider), Susan Kim (CFO), Kathy Ordonez (Director), and Mark Van Oene (COO). Learn More on Pacific Biosciences of California's active insiders.
Are insiders buying or selling shares of Pacific Biosciences of California?: During the last year, Pacific Biosciences of California insiders bought shares 1 times. They purchased a total of 40,000 shares worth more than $176,000.00. During the last year, insiders at the biotechnology company sold shares 8 times. They sold a total of 158,417 shares worth more than $776,160.97. The most recent insider tranaction occured on August, 19th when insider Jeff Eidel sold 26,760 shares worth more than $42,548.40. Insiders at Pacific Biosciences of California own 2.4% of the company. Learn More about insider trades at Pacific Biosciences of California.
Information on this page was last updated on 8/19/2024.

Peter Fromen Insider Trading History at Pacific Biosciences of California

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/11/2022	Sell	19,720	$14.30	$281,996.00

Peter Fromen Buying and Selling Activity at Pacific Biosciences of California

Pacific Biosciences of California Company Overview

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

Today's Range

Now: $1.80

$1.70

$1.89

50 Day Range

MA: $1.91

$1.55

$2.65

2 Week Range

Now: $1.80

$1.16

$10.65

Volume

8,724,995 shs

Average Volume

12,568,518 shs

Market Capitalization

$492.95 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.01

Financial Prophecy

From Porter & Company | Ad

The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.

Including the name of the #1 company to buy.